ThomasArmstrongHopeMD

PubMed

• 26 citations
  Tumor Response to Radiopharmaceutical Therapies: The Knowns and the Unknowns
  George Sgouros, Yuni K. Dewaraja, Freddy E. Escorcia, Stephen A. Graves, Thomas A. Hope
  Journal of Nuclear Medicine. 2021-12-01
• 186 citations
  The North American Neuroendocrine Tumor Society Consensus Paper on the Surgical Management of Pancreatic Neuroendocrine Tumors
  James R. Howe, Nipun B. Merchant, Claudius Conrad, Xavier M. Keutgen, Julie Hallet
  Pancreas. 2020-01-01
• 76 citations
  The North American Neuroendocrine Tumor Society Consensus Guidelines for Surveillance and Medical Management of Pancreatic Neuroendocrine Tumors.
  Thorvardur R Halfdanarson, Jonathan R Strosberg, Laura Tang, Andrew M Bellizzi, Emily K Bergsland
  Pancreas. 2020-08-01

Journal Articles

• First-in-Human Phase I Study of CTT1057, a Novel 18F Labeled Imaging Agent with Phosphoramidate Core Targeting Prostate Specific Membrane Antigen in Prostate Cancer  
  Spencer C Behr, Hao G Nguyen, Thomas A Hope, Kirsten L Greene, Matthew R Cooperberg, Robert R Flavell, Eric J Small, Peter R Carroll, Journal of Nuclear Medicine
• Tumor Cell Heterogeneity and Resistance; Report from the 2018 Coffey‐Holden Prostate Cancer Academy Meeting  
  Thomas A Hope, Kenneth J Pienta, Fatima Karzai, Simpa S Salami, Robert B Den, The Prostate
• Impact of Long-Term Androgen Deprivation Therapy on PSMA Ligand PET/CT in Patients with Castration-Sensitive Prostate Cancer  
  Thomas Hope, MD, European Journal of Nuclear Medicine and Molecular Imaging